OACC
Oaktree Acquisition Corp. III Life Sciences10.60
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
260.58MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
10-Q
8-K
New biotech expert joins board
Oaktree Acquisition Corp. III Life Sciences appointed David A. Berry, MD, PhD, as an independent director on October 17, 2025, adding him to the audit, nominating, and compensation committees. With deep biotech roots as co-founder of Averin Capital and former CEO of Valo Health, Seres Therapeutics, and others, Berry brings sharp expertise to the SPAC's board. No compensation for his role. This bolsters governance ahead of a potential life sciences merger.
10-Q
Q2 FY2025 results
Oaktree Acquisition Corp. III Life Sciences posted net income of $1.9M for Q2 2025 ended June 30, driven by $2.1M in interest from its $198M trust account, offsetting $270K in administrative costs—its sole operations as a blank check company hunting life sciences targets. Six-month net income hit $3.5M on $4.2M interest against $715K expenses, with EPS at $0.14 per share across 19.2M redeemable Class A and 5.4M non-redeemable shares, reconciling neatly without dilution flags. Cash outside trust stands at $1.4M, bolstered by a $250K withdrawal for working capital, while a $12K related-party note lingers and no debt burdens the balance sheet. No business combination yet, but trust accretion to $10.29 per share signals steady value build. Sponsor pays $25K monthly for admin support. Still, failure to seal a deal within 24 months risks full liquidation.
8-K
CFO resigns; Sweeney appointed
Oaktree Acquisition Corp. III Life Sciences announced on June 3, 2025, the resignation of CFO Courtney Conigliaro to pursue other opportunities, with no disagreements cited. The board immediately appointed Thomas Sweeney, a seasoned Oaktree Capital Management executive and CPA, as the new CFO without compensation or employment agreement. Sweeney brings deep expertise from overseeing finance for Oaktree's private credit and BDCs. This leadership shift bolsters internal financial oversight. Audit committee chair Alvin Shih was confirmed.
10-Q
Q1 FY2025 results
Oaktree Acquisition Corp. III Life Sciences posted a net income of $1.7M for Q1 FY2025 ended March 31, 2025, driven by $2.1M in interest from its Trust Account, offsetting $0.4M in general and administrative expenses—its sole operating cost as a blank check company. The Trust swelled to $195.7M at $10.19 per redeemable share, up from $193.6M at year-end, while outside cash dipped to $1.3M amid routine outflows. No revenue yet, but interest momentum covers the hunt for a life sciences target. Diluted EPS hit $0.07 across 24.6M shares, fully reconciled with no anti-dilution quirks. Liquidity holds firm with no debt beyond a minor related-party note. No M&A or non-GAAP metrics disclosed in the 10-Q. Sponsor lockup adds stability, yet geopolitical tensions could snag the deal.
IPO
Sector
Industry
AACB
Artius II Acquisition Inc.
10.31+0.00
BACC
Blue Acquisition Corp.
10.24+0.00
BLUW
Blue Water Acquisition Corp. II
10.25-0.04
CCII
Cohen Circle Acquisition Corp.
10.23-0.03
IPCX
Inflection Point Acquisition Co
10.11+0.00
JACS
Jackson Acquisition Company II
10.42+0.00
LCCC
Lakeshore Acquisition III Corp.
10.21+0.00
LOKV
Live Oak Acquisition Corp. V
10.27+0.02
OAKU
Oak Woods Acquisition Corporati
12.05+0.00
TVA
Texas Ventures Acquisition III
10.50-0.01